ライフサイエンスコーパス: cyclosporine

1 with reduced cellular toxicity compared with cyclosporine.

2 ith high-dose prednisolone, methotrexate and cyclosporine.

3 including cyclophosphamide, vincristine, and cyclosporine.

4 centiles, and history of using prednisone or cyclosporine.

5 ot genotype 1b, had increased sensitivity to cyclosporine.

6 compatible groups and were not suppressed by cyclosporine.

7 ns of cytotoxic T-lymphocyte antigen 4-Ig or cyclosporine.

8 often treated with steroids, rituximab, and cyclosporine.

9 r standard-dose cyclosporine or reduced-dose cyclosporine.

10 dard of care 40 years after the discovery of cyclosporine.

11 release, and 152 at-risk patients receiving cyclosporine.

12 JW47, using a quinolinium cation tethered to cyclosporine.

13 Interventions: Short course (3-7 days) of cyclosporine.

14 en and the less-intensive regimen) than with cyclosporine.

15 NS2 modulates sensitivity of HCV to cyclosporines.

16 Treatment consisted of steroids and cyclosporine (1), pacemaker placement for sick sinus syn

17 reports with definite evidence (quinine, 34; cyclosporine, 15; tacrolimus, 12).

18 al dexamethasone 40 mg for days 1 to 4, oral cyclosporine 2.5 to 3 mg/kg daily for day 1 to 28, and i

19 Topical liposomal formulation of cyclosporine, 2.0% w/w, is effective in treatment of lim

20 s received an intravenous bolus injection of cyclosporine, 2.5 mg/kg, at the onset of advanced cardio

21 isted of mycophenolate mofetil (28 days) and cyclosporine (35 days).

22 ere included in intention-to-treat analysis (cyclosporine, 400; control, 394).

23 Cyclosporine (66.4%), methotrexate (47.3%), azathioprine

24 ts were randomized to receive an IV bolus of cyclosporine A (10 mg/kg) or normal saline (placebo, con

25 ipients (RTX) receiving tacrolimus (n=34) or cyclosporine A (CsA) (n=24) or an mTORi (n=26).

26 monly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluoromethol

27 antly, a pharmacological inhibition of CN by cyclosporine A (CsA) ameliorated the alpha-syn-induced l

28 ated in DHHC5-deficient hearts, inhibited by cyclosporine A (CsA) and adenosine, promoted by staurosp

29 whereas inhibitors of immunophilins, such as cyclosporine A (CsA) and FK506, inhibited CrkII, but not

30 te mofetil (MMF) or Everolimus combined with cyclosporine A (CsA) and steroids.

31 on of rituximab to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for newly dia

32 s are administered the calcineurin inhibitor cyclosporine A (CsA) chronically and demonstrate an incr

33 Here we show that AS and cyclosporine A (CsA) exerted synergistic inhibitory effe

34 Whether cyclosporine A (CsA) has beneficial effects in reperfuse

35 Cyclosporine A (CsA) increases beta-catenin messenger RN

36 It has been suggested that cyclosporine A (CsA) induces gingival enlargement by pro

37 Cyclosporine A (CsA) is a well-known immunosuppressive a

38 Cyclosporine A (CsA) is an immunosuppressive drug which

39 Cyclosporine A (CsA) is used for the treatment of psoria

40 mic or pharmacological postconditioning with cyclosporine A (CsA) might protect the kidney from letha

41 Patients with acute GvHD are treated with cyclosporine A (CsA) or tacrolimus (FK506), which not on

42 s of 3-8 or 6-12 ng/mL plus reduced-exposure cyclosporine A (CsA) or to mycophenolic acid (MPA) 1.44

43 after renal transplantation) conversion from cyclosporine A (CsA) to everolimus versus continued CsA

44 warm ischemia), and rats subjected to acute cyclosporine A (CSA) toxicity (50 mg/kg for 2 d intraper

45 the RNA-induced silencing complex (RISC) of cyclosporine A (CsA) treated and control human proximal

46 nts randomized (2:1) to sirolimus (n=314) or cyclosporine A (CsA) treatment (n=161).

47 ive strategies combining tacrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) an

48 Cyclosporine A (CsA), a mitochondrial permeability trans

49 The PLGA-GA NS loaded with cyclosporine A (CsA), a model peptide, upon peroral dosi

50 terestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to preve

51 treated with immunosuppressant drugs such as cyclosporine A (CsA), an inhibitor of calcineurin phosph

52 more than that of M6G (80.31 +/- 21.75 muM); Cyclosporine A (CsA), an inhibitor of OATP2B1, can inhib

53 splant recipients treated with prednisolone, cyclosporine A (CsA), and mycophenolate sodium (MPS) for

54 ly treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and prednisone (pred).

55 ugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), are often used together after HSCT

56 y side effect of the immunosuppressive drug, cyclosporine A (CsA), can be a major issue in transplant

57 of AM19 and AM1c9, secondary metabolites of cyclosporine A (CsA), have been associated with nephroto

58 in mice treated with a potent SC activator, cyclosporine A (CSA), which inhibits the phosphatase cal

59 oxidase 2 (Nox2) plays an important role in cyclosporine A (CsA)-induced chronic hypoxia.

60 s of fibrosis-related IL-6-type cytokines in cyclosporine A (CsA)-induced gingival overgrowth (GO).

61 Recipients were immunosuppressed either with cyclosporine A (CsA, 1.5 mg/kg/day subcutaneously) or wi

62 nd during infusion (6, 12, or 24 mg/kg/h) of cyclosporine A (CsA, a P-glycoprotein [P-gp] inhibitor).

63 Tacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2

64 from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regar

65 The mean doses of cyclosporine A (mg/kg/day) were recorded.

66 clobetasol, or in combination with systemic cyclosporine A and anti-alphabeta-T-cell receptor antibo

67 ium opens the channel, which is inhibited by cyclosporine A and ATP/ADP.

68 Experiments using cyclosporine A and cardiac-specific CaMKIIdelta knockout

69 Calcineurin inhibitors such as cyclosporine A and FK506 are effective immunosuppressant

70 A-matched related donor and prophylaxis with cyclosporine A and methotrexate were associated with low

71 The immunosuppressive natural products cyclosporine A and sanglifehrin A inhibit the enzymatic

72 Cyclosporine A and tacrolimus significantly reduced IFNg

73 n was strongly potentiated by combination of cyclosporine A and UVA treatment.

74 bunit ring and unhooks it from cyclophilin D/cyclosporine A binding sites in the ATP synthase F1, pro

75 Partial blocking of AIF release by cyclosporine A in OmpU-treated cells further suggests th

76 ucted from June 22, 2010, to March 13, 2013 (Cyclosporine A in Out-of-Hospital Cardiac Arrest Resusci

77 In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction

78 or PLCgamma2 or inhibiting calcineurin with cyclosporine A leads to increased expression of PD-1 lig

79 125 and cyclosporine A) and differentiation (cyclosporine A only) of osteoclast precursors.

80 aling pathway in lymphoma cells, either with cyclosporine A or anti-CD1d blocking antibody, prolonged

81 hat short term (4-6 h) treatment with 15 muM cyclosporine A or FK506 rescues the pre-formed immature

82 indicated that inhibition of calcineurin by cyclosporine A or knockdown of NFATc4 using small interf

83 with chaperone Hsp70, and the treatment with cyclosporine A reduces the association of mutant P-gp, t

84 ion with costimulation blockade and low-dose cyclosporine A resulted in a complete deletion of periph

85 Cyclosporine A selectively ameliorated the Anesthesia/Su

86 Cyclosporine A stabilizes Ets-2 mRNA and protein when th

87 We previously demonstrated that cyclosporine A treatment during resuscitation can signif

88 keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD pat

89 Cyclosporine A treatment reduced renal expression and se

90 We hypothesized that cyclosporine A treatment would attenuate myocardial and

91 idized to total glutathione ratio induced by cyclosporine A treatment.

92 Cyclosporine A was used to enhance levels of the PET rad

93 HLA mismatches and cyclosporine A were independently associated with increa

94 -principle, the known binding interaction of Cyclosporine A with cyclophilin A protein in a yeast cel

95 -dependent migration (including SP600125 and cyclosporine A) and differentiation (cyclosporine A only

96 20-30% by calcineurin inhibitors (FK506 and cyclosporine A).

97 neuronal co-cultures through the addition of cyclosporine A, a potent immune-modulator.

98 ubating cells with the cyclophilin inhibitor cyclosporine A, a treatment that triggered efficient ER

99 Cyclosporine A, an inhibitor of mitochondria permeabilit

100 rapies using calcineurin inhibitors, such as cyclosporine A, are associated with a higher incidence o

101 e agents, azathioprine, 6-mercaptopurine and cyclosporine A, are compatible with pregnancy.

102 N-acetyl-L-cysteine and cyclosporine A, blocked ethanol and acetaldehyde-induced

103 tide) and a model hydrophobic macromolecule (Cyclosporine A, CsA), herein we provide a mechanistic un

104 three specific calcineurin inhibitors FK506, cyclosporine A, or calcineurin inhibitory peptide preven

105 Ca(2+) signaling or calcineurin with BAPTA, cyclosporine A, or FK506 prevented activation of NF-kapp

106 tochondrial Ca(2+) influx, by mPTP inhibitor cyclosporine A, sanglifehrin, and in cyclophilin D knock

107 Upon introducing the nephrotoxin, Cyclosporine A, the epithelial barrier is disrupted in a

108 kidneys long-term after 12 days of high-dose cyclosporine A, uniformly accepted donor-major histocomp

109 Cyclosporine A, with or without concurrent corticosteroi

110 rtrophy group (n = 5), and aortic-banded and cyclosporine A- treated cardiomyopathy group (n = 5).

111 Cyclosporine A-induced nephrotoxicity is multifactorial

112 imilar concentration as pharmaceutical grade cyclosporine A.

113 s a target of the natural products FK506 and Cyclosporine A.

114 e cellular receptor of the immunosuppressant cyclosporine A.

115 e trough level (C0) and used higher doses of cyclosporine A.

116 transplantation (HCT) and a 45-day course of cyclosporine A.

117 e trough level (C0) and used higher doses of cyclosporine A.

118 decreased sensitivity to the Rgg2 antagonist cyclosporine A.

119 nd is inhibited by the cyclophilin inhibitor cyclosporine A.

120 pulses of cyclophosphamide, vincristine, or cyclosporine A; or salvage splenectomy are considered.

121 tion were observed both in mice treated with cyclosporine, a known stimulator of the HCM response, an

122 y higher than that of the standard inhibitor cyclosporine-A (CsA).

123 Administration of cyclosporine-A to enhance graft survival demonstrated th

124 tion of the Itpr2 promoter was attenuated by cyclosporine-A.

125 had been prescribed psoralen, methotrexate, cyclosporine, acitretin, adalimumab, etanercept, inflixi

126 onary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.

127 Short-term cyclosporine administration in mice augmented the abunda

128 Cyclosporine administration rapidly normalized the abund

129 cyclosporine and daily UV exposures, dietary cyclosporine after a period of UV exposures, and bolus d

130 ntiviral state using a non-immunosuppressive cyclosporine analogue.

131 stress, but did show increased resistance to cyclosporine and a TS phenotype.

132 received cyclophosphamide at 120 mg/kg plus cyclosporine and antibacterial, antiviral, and antifunga

133 come at discharge was comparable between the cyclosporine and control groups: 7 (1.8%) vs 5 (1.3%) pa

134 rless SKH-1 mice by three protocols: dietary cyclosporine and daily UV exposures, dietary cyclosporin

135 Cyclosporine and lifitegrast, the 2 US Food and Drug Adm

136 sus-host disease prophylaxis was composed of cyclosporine and methotrexate.

137 HCV replicons, containing or lacking NS2, to cyclosporine and other direct-acting antiviral agents.

138 Chemical modification of both the cyclosporine and sanglifehrin scaffolds has produced man

139 d for effects on conidiation, hyphal growth, cyclosporine and stress resistance, and insect virulence

140 osuppressed either with cyclosporine or with cyclosporine and sunitinib.

141 We confirm that the immunosuppressive drugs cyclosporine and tacrolimus also inhibit BCR-mediated ly

142 Immunosuppressant drugs such as cyclosporine and tacrolimus but not rapamycin also inhib

143 and to assess potential differences between cyclosporine and tacrolimus.

144 is inhibited by the immunosuppressant drugs cyclosporine and tacrolimus.

145 manner superior to the calcineurin inhibitor cyclosporine and the FKBP12 ligand rapamycin.

146 iple comorbidities, concomitant therapy with cyclosporine, and a high Psoriasis Area and Severity Ind

147 ch as penicillin, immunosuppressants such as cyclosporine, and cytostatics such as bleomycin.

148 raacetate-AM acetoxymethyl ester (BAPTA-AM), cyclosporine, and inhibitor of nuclear factor of activat

149 rferon (IFN-alpha), telaprevir, daclatasvir, cyclosporine, and ribavirin, despite no prior exposure t

150 inary metabolic patterns varied over time in cyclosporine- and tacrolimus-treated patients and were s

151 Compared with anti-TNF-alpha and cyclosporine, anti-IL-12/23 treatment resulted in a grea

152 Mixed-chirality peptide macrocycles such as cyclosporine are among the most potent therapeutics iden

153 orticosteroids; other medications, including cyclosporine, are used in patients who fail to respond.

154 CypA antagonists, such as cyclosporines, are potent inhibitors of HCV replication.

155 Objective: To assess a short course of cyclosporine as first-line therapy for DIHS.

156 that the postresuscitation administration of cyclosporine attenuates myocardial and cardiac mitochond

157 with an immunosuppressive regimen including cyclosporine, azathioprine, and prednisolone.

158 AIDs were replaced by oral prednisolone with cyclosporine, azathioprine, or mycophenolate as steroid-

159 belatacept less-intensive-based (n = 71), or cyclosporine-based (n = 73) immunosuppression.

160 has been demonstrated to be as efficient as cyclosporine-based immunosuppression and is associated w

161 pt-based immunosuppression, as compared with cyclosporine-based immunosuppression, was associated wit

162 domized to cyclosporine continued to receive cyclosporine-based immunosuppression.

163 The cyclosporine-based regimen was associated with FMI decre

164 The cyclosporine-based regimen was independently associated

165 Compared with cyclosporine, belatacept was associated with improved HR

166 fferent drugs, such as PF74, CAP-1, IXN-053, cyclosporine, Bi2 (also known as BI-2), and the peptide

167 Cyclosporine blocked de novo formation of the membranous

168 However, in contrast with dietary cyclosporine, bolus dosages of cyclosporine by gavage, r

169 pt) by 106 (27.2%), acitretin by 57 (14.6%), cyclosporine by 30 (7.7%), fumaric acid esters by 19 (4.

170 r a period of UV exposures, and bolus dosing cyclosporine by gavage and repeated UV exposures.

171 with dietary cyclosporine, bolus dosages of cyclosporine by gavage, resulting in strongly varying bl

172 Patients initially randomized to cyclosporine continued to receive cyclosporine-based imm

173 none of the sites treated with conventional cyclosporine cream or placebo gel.

174 cyclosporine lipogel, 2.0%, or conventional cyclosporine cream, 2.0% w/w.

175 uced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue S

176 kidney-pancreas transplant recipients during cyclosporine (CSA) and TAC eras, analyzed by intention-t

177 o application of P2Ns was demonstrated using cyclosporine (CsA) as a model peptide.

178 stagraf XL) qd, tacrolimus (Prograf) bid, or cyclosporine (CsA) bid.

179 HIV, tacrolimus (TAC) trough levels (C0) or cyclosporine (CsA) drawn at C0 or 2 hours after dosing (

180 Cyclosporine (CsA) is an immunosuppressant that is highl

181 We recently utilized the cyclosporine (CsA) washout assay, in which TRIM-CypA-med

182 HIV-1 capsid stability were assessed using a cyclosporine (CsA) washout assay.

183 ing as defined in parallel drug addition and cyclosporine (CsA) washout assays to detect the kinetics

184 locked by the nonimmunosuppressive analog of cyclosporine (CsA), sarcosine-3(4-methylbenzoate)-CsA (S

185 ts under immunosuppressive regimens based on cyclosporine (CsA), tacrolimus (Tcr), and sirolimus (Sir

186 Groups included: no treatment, full dose cyclosporine (CsA, 10 mg/kg per day), ixazomib (0.25 mg/

187 Cyclosporine did not reduce the incidence of the separat

188 d been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes

189 with nonshockable cardiac rhythm after OHCA, cyclosporine does not prevent early multiple organ failu

190 d their efficacy in combination with reduced cyclosporine dosing in de novo heart transplant recipien

191 itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedaron

192 ate analyses, the use of Olopatadine 0.1% or cyclosporine eye drops before DALK (OR = 14.51, 95% CI =

193 of Olopatadine 0.1% or any concentration of cyclosporine eye drops prior to DALK.

194 , laser and light-based therapy, and topical cyclosporine for ocular rosacea.

195 of cyclophilins, including the approved drug cyclosporine, greatly reduced the viability of glioblast

196 A total of 395 patients in the cyclosporine group and 396 in the placebo group received

197 rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds

198 R]) ages were 63.0 (54.0-71.8) years for the cyclosporine group and 66.0 (57.0-74.0) years for the co

199 set of advanced cardiovascular life support (cyclosporine group) or no additional intervention (contr

200 Asphyxiated piglets treated with cyclosporine had lower plasma troponin and myocardial li

201 , respectively (belatacept more-intensive vs cyclosporine: hazard ratio [HR] = 0.95; 95% confidence i

202 13.9%, respectively (belatacept 4-weekly vs cyclosporine: HR = 1.06, 95% CI 0.35-3.17, P = .92; bela

203 -1.92; P = .89; belatacept less-intensive vs cyclosporine: HR = 1.61; 95% CI 0.85-3.05; P = .15).

204 I 0.35-3.17, P = .92; belatacept 8-weekly vs cyclosporine: HR = 2.00, 95% CI 0.75-5.35, P = .17).

205 s, approximately 35x10(6)) versus vehicle in cyclosporine-immunosuppressed swine with a chronic left

206 - allogeneic transplants were performed with cyclosporine immunosuppression.

207 ble) or group O (AO-compatible) donors under cyclosporine immunosuppression.

208 nous steroid therapy in 35 patients (26.5%), cyclosporine in 98 patients (74.2%), and azathioprine in

209 The early impressive results of cyclosporine in kidney transplant recipients led to its

210 ture clinical trials should assess liposomal cyclosporine in larger study populations.

211 Short courses of cyclosporine in the acute care setting may be an alterna

212 V-irradiated during peak or trough levels of cyclosporine in the blood.

213 ght be lowered with a more steady release of cyclosporine in the body.

214 The pharmacokinetics of cyclosporine in the setting of vismodegib administration

215 Attempts to use topical cyclosporine in treatment of psoriasis have failed becau

216 e, we show that endothelial cells exposed to cyclosporine in vitro and in vivo release microparticles

217 ho-NKCC2, and treatment of isolated TAL with cyclosporine increased the chloride affinity and transpo

218 esulting in strongly varying blood levels of cyclosporine, increased tumor development in chronically

219 infection was enhanced 4-fold by addition of cyclosporine, indicating that the requirement for TNPO3

220 ble to OPC, and blockade of TCR signaling by cyclosporine induced susceptibility.

221 Cyclosporine-induced microparticles caused injury to bys

222 tates exploration into the role of miRNAs in cyclosporine-induced nephrotoxicity (CIN) and the gene p

223 Cyclosporine is generally allowed in lactating women, al

224 for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole, voriconazole,

225 pid status, body mass index (BMI), and blood cyclosporine levels (C0 and C2) were determined.

226 egib administration and weekly monitoring of cyclosporine levels ensured that therapeutic immunosuppr

227 %) in DSS was seen in all sites treated with cyclosporine lipogel, (P < .001; 95% CI, 77.48-88.22).

228 ird arm comprised 7 patients randomized with cyclosporine lipogel, 2.0% or standard clobetasol propio

229 was observed after 2 weeks of treatment with cyclosporine lipogel, 2.0% w/w (P < .001; 95% CI, 13.77-

230 4 patients were randomized to receive either cyclosporine lipogel, 2.0% weight by weight (w/w), or pl

231 d arm, 7 patients were randomized to receive cyclosporine lipogel, 2.0%, or conventional cyclosporine

232 (41%) psoriasis lesional sites treated with cyclosporine lipogel, 85.7% of sites treated with clobet

233 rimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce

234 nts suggests that the mode of administrating cyclosporine may be crucial for the increased skin cance

235 was not significantly different between the cyclosporine (median, 10.0; IQR, 7.0-13.0) and the contr

236 between 1989 and 2015, prescribed any ISDs (cyclosporine, methotrexate, azathioprine, anti-TNF drugs

237 3 years posttransplant, she is maintained on cyclosporine, MMF and prednisone with no PRES recurrence

238 nance immunosuppressive regime consisting of cyclosporine, mycophenolate mofetil, and prednisolone we

239 macokinetic interaction was observed between cyclosporine, mycophenolic acid, and RAL.

240 ore (mPTP) opener, and N-methyl-4-isoleucine cyclosporine (NIM811), an mPTP inhibitor, were administe

241 We also analyzed the effects of cyclosporine on membranous web formation by electron mic

242 rial only); and (c) impact of belatacept and cyclosporine on side effect experience and HRQoL.

243 attributable mostly to a single medication, cyclosporine ophthalmic emulsion (Restasis, Allergan, Ir

244 r samples from patients treated with topical cyclosporine or corticosteroids showed a dramatic reduct

245 as 2-fold greater than the mean duration for cyclosporine or fumaric acid esters.

246 astatin, whereas combining atorvastatin with cyclosporine or mycophenolate in place of rapamycin was

247 5 or 3 mg per day, with either standard-dose cyclosporine or reduced-dose cyclosporine.

248 Allografts were immunosuppressed either with cyclosporine or with cyclosporine and sunitinib.

249 data on combining biologics with acitretin, cyclosporine, or a second biologic.

250 orticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresis, thalidomide, cyclophospham

251 Experimental evidence suggests that cyclosporine prevents postcardiac arrest syndrome by att

252 ive belatacept regimens as compared with the cyclosporine regimen (hazard ratio with the more-intensi

253 regimen, and 131 of the 215 treated with the cyclosporine regimen were followed for the full 84-month

254 th belatacept regimens but declined with the cyclosporine regimen.

255 n, a less-intensive belatacept regimen, or a cyclosporine regimen.

256 We investigated why cyclosporines require NS2 to increase their inhibitory e

257 This block was prevented by cyclosporine resistance mutations in NS5A.

258 and differential effects on conidiation and cyclosporine resistance.

259 re-intensive, belatacept less-intensive, and cyclosporine, respectively (belatacept more-intensive vs

260 A 7-day course of cyclosporine resulted in clinical resolution of the DIHS

261 A 3-day course of cyclosporine resulted in rapid and sustained clinical im

262 rsensitivity reaction that were treated with cyclosporine, resulting in rapid and significant clinica

263 ate (RR, 0.98 [95% CI, 0.78-1.23]; P = .83), cyclosporine (RR, 1.16 [95% CI, 0.48-2.80]; P = .49), an

264 th and purified recombinant BbCypA displayed cyclosporine sensitive PPIase activity.

265 es in the presence of cellular extracts in a cyclosporine-sensitive manner.

266 on-attenuated NS3-5B JFH1 RNAs, showing that cyclosporine sensitivity is linked to reduced replicatio

267 s 3 and 4 after transplantation, followed by cyclosporine starting on day 5.

268 rred, new observational studies suggest that cyclosporine, tacrolimus, and rituximab may be effective

269 is approach was validated for phylloquinone, cyclosporine, testosterone undecanoate, cabazitaxel and

270 Second, using cyclosporine, the target-to-background ratio of N-(11)C-

271 s to be a safe option for patients receiving cyclosporine therapy with routine monitoring.

272 uppressed heart transplant patient receiving cyclosporine therapy.

273 as significantly higher with tacrolimus than cyclosporine; there was no difference between the two ta

274 Switching from cyclosporine to the mTOR inhibitor rapamycin is reported

275 ns included topical corticosteroids, topical cyclosporine, topical vitamin A, oral doxycycline, punct

276 ted injury of the kidneys and vasculature in cyclosporine-treated mice.

277 o experience less side effects compared with cyclosporine-treated patients, except for dry skin.

278 reported better absolute PCSs compared with cyclosporine-treated patients.

279 s factor-a (TNF-alpha; etanercept, n=50), or cyclosporine treatment (n=50).

280 ardial function than TNF-alpha inhibition or cyclosporine treatment.

281 ined to determine the timing and efficacy of cyclosporine treatment.

282 ble in patients achieving predefined reduced cyclosporine trough concentrations.

283 , higher serum level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of

284 , higher serum level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of

285 nine, BUN, folate and vitamin B12, and blood cyclosporine trough level (C0) are independently associa

286 tinine (P=0.03), and BUN (P=0.05), and blood cyclosporine trough level (C0, P=0.005) were independent

287 Short-term cyclosporine use has been combined with etanercept or ad

288 gnificantly different between the 98 (24.5%) cyclosporine vs 101 (25.6%) control patients at hospital

289 Despite the low patient size, cyclosporine was associated with a promising significant

290 Cyclosporine was combined with azathioprine or mycopheno

291 Conclusions and Relevance: A short course of cyclosporine was of therapeutic benefit in the treatment

292 Cyclosporine was preferred for diabetic, hepatitis C-inf

293 posure, continuous dietary administration of cyclosporine was shown to inhibit tumor formation.

294 elatacept 4-weekly, belatacept 8-weekly, and cyclosporine were 11.1%, 21.9%, and 13.9%, respectively

295 elatacept 4-weekly, belatacept 8-weekly, and cyclosporine were 67.0, 68.7, and 42.7 mL/min per 1.73 m

296 l, had limitations, glucocorticosteroids and cyclosporine were the most promising systemic immunomodu

297 acy of systemic drugs are scarce, except for cyclosporine, which has been approved for the therapy of

298 t transplant, immunosuppressed with low-dose cyclosporine, who presented to a specialty dermatology t

299 totoxic medications such as methotrexate and cyclosporine, with varying degrees of success.

300 We aimed to test whether cyclosporine would improve clinical outcomes and prevent